Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-11-08
2005-11-08
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100
Reexamination Certificate
active
06962981
ABSTRACT:
The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM′) of the PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM′ allows the use of an immunoenzymatic assay for their detection.
REFERENCES:
patent: 5036003 (1991-07-01), Olander et al.
patent: 5153118 (1992-10-01), Wrightt, Jr. et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5227471 (1993-07-01), Wright, Jr.
patent: 5453359 (1995-09-01), Gargan et al.
patent: 5489525 (1996-02-01), Pastan
patent: 5538866 (1996-07-01), Israeli et al.
patent: 5643786 (1997-07-01), Cohen et al.
patent: 5773292 (1998-06-01), Bander
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6107090 (2000-08-01), Bander
patent: 6136311 (2000-10-01), Bander
patent: 6150508 (2000-11-01), Murphy et al.
patent: 0 228 243 (1987-07-01), None
patent: WO 94/02156 (1994-02-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 96/08570 (1996-03-01), None
patent: WO 96/26272 (1996-08-01), None
patent: WO 96/39185 (1996-12-01), None
patent: WO 97/35616 (1997-10-01), None
patent: WO 98/03873 (1998-01-01), None
patent: WO 02/069907 (2002-09-01), None
Roitt et al, 1993, Immunology, 3rd Edition, Mosby, St. Louis, p. 1.6, see Antibodies.
Robert M. Sharkey et al., Enhanced Clearance of Radiolabeled Murine Monoclonal Antibody by a Syngeneic Anti-Idiotype Antibody in Tumor-bearing Nude Mice, Int. J. Cancer, 1992;51:266-273.
Benjamin Tjoa et al., In Vitro Propagated Dendritic Cells From Prostate Cancer Patients as a Component of Prostate Cancer Immunotherapy, The Prostate, 1995;27:63-69.
Fernandez, et al., “Influence of Epitope Polarity and Adjuvants on the Immunogenicity and Efficacy of a Synthetic Peptide Vaccine Against Semliki Forest Virus,”Journal of Virology67: 5843-8 (1993).
Fernandez, et al., “Epitope Polarity and Adjuvants Influence the Fine Specificity of the Humoral Response Against Emliki Forest Virus Specific Peptide Vaccines,”Vaccine16:1531-6 (1998).
Holmes, “PSMA Specific Antibodies and Their Diagnostic and Therapeutic Use,”Exp. Opin. Invest.Drugs10 (3):511-519 (2001).
Beutler et al., “L-Glutamate, Colorimetric Method with Glutamate Dehydrogenase and Diaphorase, Methods of Enzymaytic Analysis,” Bergmeyer et al. Eds, 1985 VCH Publishers, Deerfield Beach, pp. 369-376.
Carter et al., “Prostate-specific Membrane Antigen is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase,”Proc. Natl. Acad. Sci. USA 93:749-751 (1996).
He Liu et al., “Monoclonal Antibodies to the Extracellular Domain of Prostate-Specific Membrane Antigen Also React with Tumor Vascular Endothelium,”Cancer Research 57:3629-3634 (1997).
Horoszewicz et al., “Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients,”Anticancer Research 7:927-936 (1987).
Israeli et al., “Molecular Cloning of A Complementary DNA Encoding a Prostate-specific Membrane Antigen,”Cancer Res. 53:227-230 (1993).
Israeli et al., “Expression of the Prostate-specific Membrane Antigen,”Cancer Res. 54:1807-1811 (1994).
Leek et al., “Prostate-Specific Membrane Antigen: Evidence for the Existence of a Second Related Human Gene,”British Journal of Cancer 72:583-588 (1995).
Murphy et al., “Comparison of Prostate Specific Antigen, prostate Specific Membrane Antigen, and LNCaP-Based Enzyme-Linked Immunosorbent Assays in Prostatic Cancer Patients and Patients With Benign Prostatic Enlargement,”The Prostate 26:164-168 (1995).
Murphy et al., “Comparison of prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients,”Anticancer Res. 15:1473-1480 (1995).
Murphy et al., “Measurement of Prostate-Specific Membrane Antigen in the Serum With a New Antibody,”The Prostate 28:266-271 (1996).
Nakamura et al., Enzyme immunoassays: heterogeneous and homogeneous systems, Handbook of Exp. Immunol. Weir et al., eds. Blackwell Scientific Publications, Oxford. 1:2711-2720 (1987).
Rochon et al., “Western Blot Assay for Prostate-Specific Membrane Antigen in Serum of Prostate Cancer Patients,”The Prostate 25:219-223 (1994).
Roitt et al.,Immunology,3rd Ed., Mosby, St. Louis, p. 106 (1993).
Su et al., “Alternatively Spliced Variants of prostate-specific Membrane Antigen RNA: Ratio of Expression as a Potential Measurement of Progression,”Cancer Res. 55:1441-1443 (1995).
Troyer et al., “Subcellular Localization of the 7E11-C5 Prostate Specific Antigen,”Proc. Am. Assoc. Cancer Res. 35:283 Abstract 1688 (1994).
Troyer et al., “Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate-Specific Membrane Antigen,”Urol. Oncol. 1:29-37 (1995).
Troyer et al., “Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids,”Int. J. Cancer 62:552-558 (1995).
Wright, “Characterization of a New prostate Carcinoma-Associated Marker: 7E11-C5,”Antibody Immunoconjugates and RadioPharmaceuticals 3: Abstract 193 (1990).
Boynton Alton L.
Holmes Eric H.
Murphy Gerald P.
Tino William Thomas
Darby & Darby
Helms Larry R.
Medarex Inc.
Yu Misook
LandOfFree
Monoclonal antibodies specific for the extracellular domain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies specific for the extracellular domain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies specific for the extracellular domain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3469815